Page last updated: 2024-12-06

triciribine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Triciribine is a potent and selective inhibitor of the enzyme cytidine monophosphate (CMP) kinase. CMP kinase is involved in the synthesis of cytidine triphosphate (CTP), an essential component of DNA and RNA. Triciribine has been shown to have antitumor activity in preclinical studies, and it is currently being investigated in clinical trials for the treatment of various types of cancer. Triciribine is synthesized through a multi-step process that involves the modification of a nucleoside analogue. The compound exhibits a unique mechanism of action, disrupting the normal functioning of CMP kinase. Triciribine's ability to inhibit CMP kinase leads to a decrease in CTP levels, thereby hindering DNA and RNA synthesis. This effect ultimately inhibits tumor cell growth and proliferation. The study of triciribine is driven by its potential as a novel anticancer agent with a distinct mechanism of action. Its selectivity for CMP kinase, along with its demonstrated antitumor activity in preclinical studies, has fueled interest in its clinical evaluation. Further research is ongoing to explore its efficacy, safety, and optimal therapeutic applications.'
```

triciribine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

triciribine : A nucleoside analogue in which the nucleobase portion is a 1,4,5,6,8-pentaazaacenaphthylene ring system substituted with an amino group at position 3, and a methyl group at position 5 and is bound to the beta-D-ribofuranosyl moiety by an N(1)-glycosidic linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65399
CHEBI ID65310
SCHEMBL ID61268
MeSH IDM0081369
PubMed CID124388827
MeSH IDM0081369

Synonyms (62)

Synonym
triciribinum [inn-latin]
1,4,5,6,8-pentaazaacenaphthylene, 3-amino-1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl-
triciribina [inn-spanish]
3-amino-1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene
1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylen-3-amine
1,4,5,6,8-pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl-
1,4,5,6,8-pentaazaacennaphthylen-3-amine, 1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl-
triciribine [inn]
brn 1171593
1,4,5,6,8-pentaazaacennaphthylen-3-amine, 1,5-dihydro-5-methyl-1-.beta.-d-ribofuranosyl-
tricyclic nucleoside
35943-35-2
TCN ,
pentaazacentopthylene
NCGC00092314-02
api-2
nsc 154020
BIOMOLKI2_000078
chebi:65310 ,
dtxsid6045743 ,
tricirbine
cas-35943-35-2
dtxcid4025743
tox21_111192
CCG-100678
triciribina
2421hmy9n6 ,
unii-2421hmy9n6
triciribinum
bdbm50369528
HY-15457
CS-0968
BCPP000034
triciribine hydrate
5-methyl-1-(beta-d-ribofuranosyl)-1,5-dihydro-1,4,5,6,8-pentaazaacenaphthylen-3-amine
S1117
triciribine [who-dd]
3-amino-1,5-dihydro-5-methyl-1-.beta.-d-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene
BRD-K80431395-001-01-6
SRI-10809-03
SCHEMBL61268
smr002530325
MLS006011145
tox21_111192_1
1,5-dihydro-5-methyl-1-?-d-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylen-3-amine
(2r,3r,4s,5r)-2-(3-amino-5-methyl-1,4,5,6,8-pentaazaacenaphthylen-1(5h)-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
AC-32686
AKOS024456958
EX-A415
api-2;triciribine
NCGC00092314-06
DB12405
HMS3677I03
Q25326616
HMS3413I03
BRD-K80431395-001-09-9
nsc-800957
nsc800957
(2r,3r,4s,5r)-2-(5-amino-7-methyl-2,6,7,9,11-pentazatricyclo[6.3.1.04,12]dodeca-1(12),3,5,8,10-pentaen-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol
triciribine
SW219112-1
PD062049

Research Excerpts

Overview

Triciribine is a tricyclic nucleoside. It inhibits human immunodeficiency virus type 1 (HIV-1) replication by a unique mechanism not involving the inhibition of enzymes directly involved in viral replication.

ExcerptReferenceRelevance
"Triciribine (TCN) is a tricyclic nucleoside that inhibits human immunodeficiency virus type 1 (HIV-1) replication by a unique mechanism not involving the inhibition of enzymes directly involved in viral replication. "( Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
Buckheit, RW; Drach, JC; Gentry, BG; Hartman, TL; Osterling, MC; Ptak, RG; Townsend, LB; Watson, KM, 2010
)
2.05

Toxicity

ExcerptReferenceRelevance
" TCN inhibited the replication of all four types of cells propagated in suspension culture; however, Novikoff cells were several times more sensitive than were the other three cell types, despite the finding that the TCN-MP, probably the main toxic principle, accumulated to about the same concentration in cells of all four lines."( Transport, phosphorylation, and toxicity of a tricyclic nucleoside in cultured Novikoff rat hepatoma cells and other cell lines and relase of its monophosphate by the cells.
Plagemann, PG, 1976
)
0.26

Pharmacokinetics

ExcerptReferenceRelevance
" Clinical development of TCNP has been hampered by high pharmacokinetic variability due to complex interplay of TCN-TCNP conversion and reconversion in plasma, erythrocytes (RBC) and peripheral organs."( Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies.
Ahuja, VK; Mahesh K U, H; Narayanan, S; Ramesh, N; Shandil, RK; Shanmugam, SS; Surendran, N, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitorAn inhibitor of phosphatidylinositol 3-kinase, EC 2.7.1.137, a family of related enzymes capable of phosphorylating the 3 position hydroxy group of the inositol ring of a phosphatidylinositol.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression011

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.18640.006038.004119,952.5996AID1159521; AID1159523
PPM1D proteinHomo sapiens (human)Potency0.37030.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency9.73910.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency6.74580.000714.592883.7951AID1259368; AID1259392
AR proteinHomo sapiens (human)Potency0.81880.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency1.88340.001022.650876.6163AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency12.58930.01237.983543.2770AID1346984
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency1.06820.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency1.04740.003041.611522,387.1992AID1159552; AID1159553; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency2.44070.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.20780.000229.305416,493.5996AID1259244; AID1259248; AID743079; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency15.72890.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency1.33330.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency21.13170.001628.015177.1139AID1259385
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency0.28180.10009.191631.6228AID1346983
Histone H2A.xCricetulus griseus (Chinese hamster)Potency43.84420.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency1.41100.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency14.96010.037617.082361.1927AID1259364
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency8.51020.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency2.11320.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency0.37030.00339.158239.8107AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency7.49780.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency2.11320.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency33.49150.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency33.49150.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.03500.00011.076810.0000AID200157; AID200159; AID241930
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (170)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (628)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID576152Cytotoxicity against human CEM-SS cells by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720379Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720424Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720080Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720417Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720073Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720054Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID241930Inhibitory concentration against human immunodeficiency virus type 1 reverse transcriptase2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-methyl-1-(beta-D-ribofuranosyl)- and 3-amino-5-methyl-1-(2-deoxy-beta-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,7
AID363633Cytotoxicity against human MDA-MB-231 cells in presence of 10 uM chloroquine by SRB assay relative to control2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720091Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720040Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363626Cytotoxicity against human MDA-MB-468 cells by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720468Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720241Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720427Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720201Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720360Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720128Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720086Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720446Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720036Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID720326Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720325Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720186Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720357Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720436Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720142Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576185Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 2 CDC 3103192010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720483Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720196Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720083Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720244Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID200157Antiviral activity was evaluated by RT (reverse transcriptase) activity in cells acutely infected with HIV-12000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
6-N-Acyltriciribine analogues: structure-activity relationship between acyl carbon chain length and activity against HIV-1.
AID720059Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720320Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720187Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720055Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720255Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576385Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720452Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720173Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720039Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720454Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID46233Intracellular phosphorylation (100 uM) in uninfected CEM-SS cells was studied after 5 hrs of Incubation.2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
6-N-Acyltriciribine analogues: structure-activity relationship between acyl carbon chain length and activity against HIV-1.
AID575955Antiviral activity against Human immunodeficiency virus 1 subtype A RW/92/016 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720198Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720456Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720230Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720242Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720280Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID46224Intracellular phosphorylation (10 uM) in uninfected CEM-SS cells after 5 hrs of incubation time2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720333Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576181Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 JV 10832010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720171Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576200Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720021Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720094Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720113Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720441Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576190Therapeutic index, ratio of TC50 for human MDM cells to IC50 for Human immunodeficiency virus 1 BAL2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID91186Compound was tested for its ability to inhibit hepatitis C viral RNA replication in Huh-7 cells (human hepatoma cells)2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Synthesis of new 2'-beta-C-methyl related triciribine analogues as anti-HCV agents.
AID720451Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720147Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720277Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576381Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720046Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720183Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576382Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720069Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720312Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID82421Tested for visual cytotoxicity on uninfected HFF cells2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720068Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720117Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720038Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720294Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720089Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720157Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720274Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720151Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720474Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720481Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720129Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720368Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1241751Antiviral activity against HIV2 by XTT assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID99613Tested in vitro for cytotoxicity against murine L1210 leukemic cells2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720464Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720340Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720074Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720430Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363644Cytotoxicity against human 184B5 cells at 20 uM chloroquine by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID576145Antiviral activity against Human immunodeficiency virus 2 CDC 310319 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID82256Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
6-N-Acyltriciribine analogues: structure-activity relationship between acyl carbon chain length and activity against HIV-1.
AID720266Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720116Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720076Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576148Antiviral activity against simian immunodeficiency virus 69R infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID576144Antiviral activity against Human immunodeficiency virus 1 subtype O BCF03 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720317Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576165Antiviral activity against 5 x 10'3 cells/well Human immunodeficiency virus 1 infected in human ACH2 cells assessed as inhibition of viral Reverse transcriptase after 3 days by [3H]TTP incorporation assay in presence of 5 ng/ml tumor necrosis factor alpha2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720050Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720405Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720284Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720382Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720394Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576153Cytotoxicity against human CEM-SS cells infected with Human immunodeficiency virus 1 SK1 by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720096Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID248015Inhibitory concentration against human cytomegalovirus using plaque assay2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-methyl-1-(beta-D-ribofuranosyl)- and 3-amino-5-methyl-1-(2-deoxy-beta-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,7
AID720237Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720107Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720334Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720304Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720372Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720115Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720390Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720136Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720296Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720138Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720292Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720306Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID46227Intracellular phosphorylation (10 uM) in uninfected CEM-SS cells was studied after 5 hrs of Incubation.2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
6-N-Acyltriciribine analogues: structure-activity relationship between acyl carbon chain length and activity against HIV-1.
AID720101Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576143Antiviral activity against Human immunodeficiency virus 1 subtype O BCF02 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID576203Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720265Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720387Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720097Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576173Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 WEJO2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720435Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP122013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720236Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1636906Inhibition of DOT1L (unknown origin) at 200 uM using chicken nucleosome as substrate in presence of [3H]SAM incubated for 1 hr by TopCount method2016Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18
New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.
AID720399Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720303Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720438Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720248Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720239Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720045Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720324Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576164Cytotoxicity against human ACH2 cells infected with latent Human immunodeficiency virus 1 by MTS assay in presence of tumor necrosis factor alpha2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720195Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720398Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720066Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720243Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576202Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID576167Antiviral activity against Human immunodeficiency virus 1 BAL infected in human MDM cells assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID200159Antiviral activity was tested in cells acutely infected with HIV-1 RT (reverse transcriptase)2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720429Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720484Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576199Cytotoxicity against human AA5 cells by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720189Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720118Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576192Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720457Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720425Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720229Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720477Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720392Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720217Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576177Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 BR/92/0252010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720249Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID575959Antiviral activity against Human immunodeficiency virus 1 subtype E CMU02 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720020Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID575952Antiviral activity against Human immunodeficiency virus 1 TEKI infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720160Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID82407HCMV plaque assay was performed using HFF cells and effect was calculated as a percentage of reduction in number of plaques2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID363641Cytotoxicity against human 184B5 cells by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720431Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576142Antiviral activity against Human immunodeficiency virus 1 subtype O BCF01 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720434Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP122013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720026Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720261Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720082Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720339Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720376Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720220Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576169Cytotoxicity against human MDM cells infected with Human immunodeficiency virus 1 BAL by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720226Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720222Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720135Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576380Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID363640Cytotoxicity against human MCF7 cells in presence of 20 uM chloroquine by SRB assay relative to control2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720467Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720143Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720327Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID46229Intracellular phosphorylation (100 uM) in uninfected CEM-SS cells after 5 hrs of incubation time2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720110Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576183Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 BCF022010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720124Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID91052Cytotoxicity using HCV replicon assay2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Synthesis of new 2'-beta-C-methyl related triciribine analogues as anti-HCV agents.
AID575960Antiviral activity against Human immunodeficiency virus 1 subtype F BR/93/020 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720085Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720181Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720257Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720335Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720105Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720482Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720336Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576392Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720450Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID46236Intracellular phosphorylation (330 uM) in uninfected CEM-SS cells after 5 hrs of incubation time2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720330Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720232Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720179Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720218Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720302Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576151Cytotoxicity against human PBMC by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720271Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720351Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720070Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720366Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720153Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720233Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720149Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720095Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720169Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720267Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720194Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720422Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576141Antiviral activity against Human immunodeficiency virus 1 subtype G JV 1083 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720114Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720215Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720023Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720042Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720167Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720159Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720087Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID720019Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720258Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720470Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576187Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Simian immunodeficiency virus Mac2512010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720204Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720154Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363630Cytotoxicity against human MDA-MB-468 cells in presence of 20 uM chloroquine by SRB assay relative to control2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720112Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720064Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720288Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576163Cytotoxicity against human ACH2 cells infected with latent Human immunodeficiency virus 1 by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID576188Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Simian immunodeficiency virus 69R2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720099Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720305Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720148Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720103Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720356Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576161Cytotoxicity against human U1 cells infected with latent Human immunodeficiency virus 1 by MTS assay in presence of tumor necrosis factor alpha2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720071Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720223Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576191Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720188Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720278Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720273Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720252Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720338Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720388Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720130Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720172Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576198Ratio of IC50 for Human immunodeficiency virus 1 H10 infected in CEM-SS cells to IC50 for Human immunodeficiency virus 1 3B infected in CEM-SS cells2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID576189Therapeutic index, ratio of TC50 for human MDM cells to IC50 for Human immunodeficiency virus 1 ADA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720058Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720025Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720466Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363647Ratio of GI50 for human 184B5 cells to GI50 for human MDA-MB-231 cells in presence of 20 uM chloroquine2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720310Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363635Cytotoxicity against human MDA-MB-231 cells in presence of 20 uM chloroquine by SRB assay relative to control2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720231Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720245Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID42124Antiviral activity against HSV-1 was determined using BSC-1 cells by an enzyme-linked immunosorbent assay (ELISA)2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
6-N-Acyltriciribine analogues: structure-activity relationship between acyl carbon chain length and activity against HIV-1.
AID720161Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720393Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720269Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576166Antiviral activity against Human immunodeficiency virus 1 ADA infected in human MDM cells assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720081Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720323Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720365Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720126Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720033Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720041Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720439Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720211Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720263Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720291Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720168Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720268Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720420Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720293Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720473Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576378Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720259Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720443Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720440Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720121Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720371Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1241749Antiviral activity against HIV assessed as inhibition of syncytial plaque formation at 0.1 uM2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID720092Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720322Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576171Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 SLKA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720134Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720084Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1241750Antiviral activity against HIV1 by XTT assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID720381Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720313Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720361Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720375Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720212Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720247Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720447Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720458Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720370Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720301Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363634Cytotoxicity against human MDA-MB-231 cells in presence of 20 uM chloroquine by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720170Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720480Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576162Antiviral activity against Human immunodeficiency virus 1 infected in human U1 cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID363646Ratio of GI50 for human 184B5 cells to GI50 for human MDA-MB-231 cells2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID576186Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 2 CDC 3103422010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720234Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720279Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576178Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 UG/92/0462010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720213Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720072Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576391Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720308Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID248202Inhibitory concentration against human herpes simplex virus type 1 using ELISA test2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-methyl-1-(beta-D-ribofuranosyl)- and 3-amino-5-methyl-1-(2-deoxy-beta-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,7
AID720472Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720250Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720192Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID471286Binding affinity to fluorescein-labeled 20mer stem loop 3 HIV1 RNA of packaging element psi by titration method2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Identification of specific small molecule ligands for stem loop 3 ribonucleic acid of the packaging signal Psi of human immunodeficiency virus-1.
AID720108Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576149Cytotoxicity against human PBMC assessed as cell viability at 10 uM by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720162Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720018Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720238Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720202Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720459Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720406Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720156Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720396Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576175Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 RW/92/0162010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720260Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720311Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720214Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720024Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576383Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720158Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576157Cytotoxicity against human H9 cells by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720359Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720270Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID575953Antiviral activity against Human immunodeficiency virus 1 WEJO infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720407Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363628Cytotoxicity against human MDA-MB-468 cells in presence of 10 uM chloroquine by SRB assay relative to control2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID576204Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720146Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720139Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720254Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576168Cytotoxicity against human MDM cells infected with Human immunodeficiency virus 1 ADA by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID576184Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 BCF032010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720104Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576146Antiviral activity against Human immunodeficiency virus 2 CDC 310342 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720344Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720300Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576389Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720132Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720419Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720200Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720035Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720127Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576147Antiviral activity against simian immunodeficiency virus Mac251 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720299Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720386Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720256Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720191Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720408Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720227Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720246Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576390Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720437Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720449Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720411Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363631Cytotoxicity against human MDA-MB-231 cells by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720175Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720380Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576160Cytotoxicity against human U1 cells infected with latent Human immunodeficiency virus 1 by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720287Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720177Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720465Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720164Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720445Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID46228Intracellular phosphorylation (100 uM) in uninfected CEM-SS cells after 12 hrs of incubation time2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720119Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID46223Intracellular phosphorylation (10 uM) in uninfected CEM-SS cells after 12 hrs of incubation time2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720286Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720391Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720030Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID82425Visual cytotoxicity was scored on uninfected HFF cells2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
6-N-Acyltriciribine analogues: structure-activity relationship between acyl carbon chain length and activity against HIV-1.
AID720210Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720199Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720056Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720109Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720206Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720165Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576172Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 TEKI2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720345Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720123Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720442Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720061Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720044Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720140Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576197Antiviral activity against Human immunodeficiency virus 1 harboring plasmid TAK-1 infected in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720043Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576196Antiviral activity against Human immunodeficiency virus 1 harboring plasmid NL4-3 infected in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720125Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720400Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720276Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720178Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720418Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720460Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID575957Antiviral activity against Human immunodeficiency virus 1 subtype C BR/92/025 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720410Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720349Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-352013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720341Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576386Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID576174Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 MDR 7692010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720032Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576387Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID576170Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 ROJO2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720078Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363637Cytotoxicity against human MCF7 cells in presence of 10 uM chloroquine by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID95489Inhibition of KB cell growth was assessed2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720374Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720098Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576155Antiviral activity against Human immunodeficiency virus 1 SK1 infected in human CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720052Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576159Antiviral activity against Human immunodeficiency virus 1 SK1 infected in human H9 cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720067Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID575951Antiviral activity against Human immunodeficiency virus 1 SLKA infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720475Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720315Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720141Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720077Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720364Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576194Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720180Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID575958Antiviral activity against Human immunodeficiency virus 1 subtype D UG/92/046 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720176Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720224Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363627Cytotoxicity against human MDA-MB-468 cells in presence of 10 uM chloroquine by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720133Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720297Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720373Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720272Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720478Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576193Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID576384Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720017Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID247776Visual cytotoxicity was determined in uninfected HFF cells using plaque assay2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-methyl-1-(beta-D-ribofuranosyl)- and 3-amino-5-methyl-1-(2-deoxy-beta-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,7
AID720413Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720264Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720225Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720298Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720062Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID46456Tested for visual cytotoxicity on uninfected CEM-SS cells2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID363639Cytotoxicity against human MCF7 cells in presence of 20 uM chloroquine by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720369Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720090Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID575950Antiviral activity against Human immunodeficiency virus 1 ROJO infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720314Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720137Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720031Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720455Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720282Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720060Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID247702Inhibitory concentration was determined for KB cell growth2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-methyl-1-(beta-D-ribofuranosyl)- and 3-amino-5-methyl-1-(2-deoxy-beta-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,7
AID720205Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720461Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576201Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720397Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720022Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720079Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720145Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720203Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720362Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720309Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720363Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720235Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720207Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720354Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720037Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720377Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576158Cytotoxicity against human H9 cells infected with Human immunodeficiency virus 1 SK1 by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID576156Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID363638Cytotoxicity against human MCF7 cells in presence of 10 uM chloroquine by SRB assay relative to control2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720346Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720093Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576182Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 BCF012010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720190Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720402Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363643Cytotoxicity against human 184B5 cells at 10 uM chloroquine by SRB assay relative to control2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID576150Cytotoxicity against human PBMC assessed as cell viability at 1 uM by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720029Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576379Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720462Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576176Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 3020562010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720409Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720395Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720174Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720155Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363642Cytotoxicity against human 184B5 cells at 10 uM chloroquine by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720053Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576195Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID363629Cytotoxicity against human MDA-MB-468 cells in presence of 20 uM chloroquine by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720415Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720295Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720321Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720328Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720028Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID471289Binding affinity to unlabeled 14mer stem loop 3 HIV1 RNA of packaging element psi by titration method2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Identification of specific small molecule ligands for stem loop 3 ribonucleic acid of the packaging signal Psi of human immunodeficiency virus-1.
AID720065Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720152Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720120Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720289Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720047Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720221Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720219Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720347Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720448Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720216Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720027Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576388Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720416Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID46235Intracellular phosphorylation (330 uM) in uninfected CEM-SS cells after 12 hrs of incubation time2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720389Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720240Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720048Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720290Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720378Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363632Cytotoxicity against human MDA-MB-231 cells in presence of 10 uM chloroquine by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720144Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363645Cytotoxicity against human 184B5 cells at 20 uM chloroquine by SRB assay relative to control2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720150Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720433Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 202013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720384Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720352Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID575956Antiviral activity against Human immunodeficiency virus 1 subtype B 302056 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720063Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720358Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720471Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720342Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720166Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720228Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720348Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-352013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720463Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID575954Antiviral activity against Human immunodeficiency virus 1 MDR 769 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720332Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720385Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720453Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576154Cytotoxicity against human CEM-SS cells infected with Human immunodeficiency virus 2 ROD by MTS assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720404Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID46610Visual cytotoxicity was scored on CEM-SS cells2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
6-N-Acyltriciribine analogues: structure-activity relationship between acyl carbon chain length and activity against HIV-1.
AID1241748Antiviral activity against HIV by syncytial plaque assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID720401Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720049Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID42125Antiviral activity was tested using an enzyme-linked immunosorbent assay (ELISA) to detect HSV-1 (herpes simplex virus type 1) using BSC-1 cells2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.
AID720318Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720111Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576179Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 CMU022010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720057Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720075Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720100Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720331Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720476Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID363636Cytotoxicity against human MCF7 cells by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID720479Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720432Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 202013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID96353Cytotoxicity measured as Inhibition of KB cell growth was assessed.2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
6-N-Acyltriciribine analogues: structure-activity relationship between acyl carbon chain length and activity against HIV-1.
AID720193Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720262Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID576180Therapeutic index, ratio of TC50 for human PBMC cells to IC50 for Human immunodeficiency virus 1 BR/93/0202010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
AID720329Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720208Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID9463Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
6-N-Acyltriciribine analogues: structure-activity relationship between acyl carbon chain length and activity against HIV-1.
AID720184Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720343Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720403Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720283Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720355Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720337Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720316Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720197Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720383Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720414Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720319Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720163Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720253Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720106Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720102Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720444Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720185Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720353Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720131Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720182Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720281Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720412Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720088Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720469Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720051Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720209Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720350Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720307Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720275Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720285Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720034Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720251Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720426Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720421Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720122Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720428Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720367Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720423Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (101)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (11.88)18.7374
1990's4 (3.96)18.2507
2000's21 (20.79)29.6817
2010's49 (48.51)24.3611
2020's15 (14.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.88 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index32.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (1.08%)5.53%
Reviews1 (6.25%)6.00%
Reviews2 (2.15%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
Other90 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]